127 related articles for article (PubMed ID: 37243975)
21. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
[TBL] [Abstract][Full Text] [Related]
22. Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study.
Weiner M; Leventhal B; Cantor A; Wimmer R; Berry DL; Cook B; Ducos R
Cancer; 1991 Dec; 68(11):2478-80. PubMed ID: 1933785
[TBL] [Abstract][Full Text] [Related]
23. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
Kahn JM; Pei Q; Friedman DL; Kaplan J; Keller FG; Hodgson D; Wu Y; Appel BE; Bhatia S; Henderson TO; Schwartz CL; Kelly KM; Castellino SM
Lancet Haematol; 2022 Jan; 9(1):e49-e57. PubMed ID: 34971582
[TBL] [Abstract][Full Text] [Related]
24. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
25. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
26. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma.
Hoppe BS; Hill-Kayser CE; Tseng YD; Flampouri S; Elmongy HM; Cahlon O; Mendenhall NP; Maity A; McGee LA; Plastaras JP
Ann Oncol; 2017 Sep; 28(9):2179-2184. PubMed ID: 28911093
[TBL] [Abstract][Full Text] [Related]
27. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
[TBL] [Abstract][Full Text] [Related]
28. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
29. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study.
Re A; Ferrari S; Frata P; Pizzocaro C; Crippa C; Tucci A; Facchetti F; Grazioli L; Magrini SM; Rossi G
Ann Oncol; 2008 May; 19(5):951-7. PubMed ID: 18209012
[TBL] [Abstract][Full Text] [Related]
30. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease.
Zagars G; Rubin P
Cancer; 1985 Aug; 56(4):864-73. PubMed ID: 4016677
[TBL] [Abstract][Full Text] [Related]
31. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
32. Thoracic irradiation in Hodgkin's disease: disease control and long-term complications.
Tarbell NJ; Thompson L; Mauch P
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):275-81. PubMed ID: 2105920
[TBL] [Abstract][Full Text] [Related]
33. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
34. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
35. Thallium-201 scintigraphy for assessment of a gallium-67-avid mediastinal mass following therapy for Hodgkin's disease.
Harris EW; Rakow JI; Weiner M; Agress H
J Nucl Med; 1993 Aug; 34(8):1326-30. PubMed ID: 8326393
[TBL] [Abstract][Full Text] [Related]
36. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.
Vecchi V; Pileri S; Burnelli R; Bontempi N; Comelli A; Testi AM; Carli M; Sotti G; Rosati D; Di Tullio MT
Cancer; 1993 Sep; 72(6):2049-57. PubMed ID: 7689924
[TBL] [Abstract][Full Text] [Related]
37. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
[TBL] [Abstract][Full Text] [Related]
38. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group.
Anderson H; Deakin DP; Wagstaff J; Jones JM; Todd ID; Wilkinson PM; James RD; Steward WP; Blackledge G; Scarffe JH
Br J Cancer; 1984 Jun; 49(6):695-702. PubMed ID: 6375711
[TBL] [Abstract][Full Text] [Related]
39. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
40. [Can children with Hodgkin's disease be treated with chemotherapy only?].
Balwierz W; Klekawka T; Moryl-Bujakowska A; Matysiak M; Sopyło B; Wachowiak J; Kaczmarek-Kanold M; Sońta-Jakimczyk D; Janik-Moszant A; Chybicka A; Chaber R; Kowalczyk JR; Mitura-Lesiuk M; Balcerska A; Stachowicz-Stencel T; Wysocki M; Kołtan A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Sobol G; Wieczorek M; Karolczyk G; Urbanek-Dadela A
Przegl Lek; 2010; 67(6):375-81. PubMed ID: 21344765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
